Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Interleukin-23 p19 inhibitors
8 evidence topics · 8 sources
ACG 2025 guideline: recommendations for induction and maintenance
Pivotal trial results for guselkumab and mirikizumab: ACG 2025 evidence summary
Comparison with ustekinumab and switching within the class: ACG 2025
ECCO 2026 guideline: recommendations and risankizumab trial results
Network meta-analyses: rankings of interleukin-23 p19 inhibitors
“Ater excluding JAK inhibitors, amongst biologic-naïve patients with moderately to severely active UC, risankizumab (P-score 0.86) and ozanimod (P-score 0.83) were ranked highest for induction of clinical remission (Figure 1b).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Risankizumab ranked first in the induction of histological remission (89.4%), followed by guselkumab (88.3%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Anti-p19 inhibitors, including risankizumab, subcutaneous guselkumab, and mirikizumab, were associated with the most favorable safety profiles for serious adverse events and adverse events leading to discontinuation, although confidence in safety estimates was lower.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote